Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring the transformative potential of its investigational islet cell therapy, zimislecel…
FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease, the U.S. Food and Drug Administration (FDA) has approved Dupixent…
Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO study (NCT05171647), demonstrating that its novel subcutaneous combination therapy of…
Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal shift in the dynamics of global health governance was unmistakably…
Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies, has marked a significant advancement in the treatment of acquired…
Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D.,…
Biogen Launches Global Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Biogen has officially launched its BRAVE study a pivotal, global Phase 3 clinical trial aimed at evaluating omaveloxolone in pediatric patients with Friedreich ataxia (FA). This significant development…
Amgen to Unveil Full Phase 2 MariTide Data and Cardiometabolic Research Highlights at ADA 2025 Scientific Sessions Amgen has announced that it will present comprehensive data from Part 1 of its Phase 2 clinical study for MariTide (maridebart cafraglutide), formerly…
AbbVie Reports Strong Phase 3 Results for Atogepant, Demonstrating Superiority Over Topiramate in Migraine Prevention AbbVie, a leading global biopharmaceutical company, has announced promising topline results from its pivotal Phase 3 TEMPLE clinical trial—a multicenter, randomized, double-blind, head-to-head study that…
Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant strategic partnership for the development and eventual commercial delivery of…
BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition BioMarin Pharmaceutical and Inozyme Pharma today announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction valued at approximately $270 million in…
WuXi AppTec Recognized Among Top 10 “Most Honored Companies” in Extel 2025 Asia Executive Team Rankings, Continuing its Global Leadership in Innovation and Drug Discovery Services WuXi AppTec, a leading global company that provides a broad portfolio of research and…